Schrewsbury, MA, United States of America

Anna M Ericsson

USPTO Granted Patents = 58 (Patent Applications = 29)

CIPO Patents = 6 (Patent Applications = 13)

EPO Patents = 18 (Patent Applications = 25)

Average Co-Inventor Count = 8.4

ph-index = 16

Forward Citations = 759(Granted Patents)

Forward Citations (Not Self Cited) = 578(Dec 10, 2025)

Location History:

Quebec, CA (1999)
Schrewsbury, MA (US) (2008)
Acton, MA (US) (2017 - 2018)
Shrewsbury, MA (US) (2002 - 2024)

Company Filing History:

29 out of 125

Forma Therapeutics, Inc.

Novo Nordisk Healthcare Ag

patents

4. 5 out of 4,179

Abbott Laboratories Corporation

Bristol-myers Squibb Compnay

Basf Aktiengesellschaft

patents

9. 1 out of 15

Valo Early Discovery, Inc.

11. 1 out of 832,843

Other

patents

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

CREB Binding Protein

Cyclic AMP-Responsive Element-Binding Protein

Pyruvate Kinase R

Isocitrate Dehydrogenase Inhibitors

Ubiquitin-Specific Protease 7 Inhibitors

Bromodomain Inhibitors

Chemokine Receptor Antagonists

Tricyclic Compounds

Pyrrolopyrrole Compositions

Quinolinone Derivatives

Indazole Compounds

Benzisoxazole Kinase Inhibitors

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378242 - Inhibiting CREB binding protein (CBP) (2025-08-05),

2. 12351577 - Inhibiting cyclic AMP-responsive element-binding protein (CREB) (2025-07-08),

3. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

4. 12128035 - Activating pyruvate kinase R (2024-10-29),

5. 12122778 - Activating pyruvate kinase R (2024-10-22),

6. 12071440 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2024-08-27),

7. 12053458 - Treating sickle cell disease with a pyruvate kinase R activating compound (2024-08-06),

8. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2024-06-25),

9. 11980611 - Treating sickle cell disease with a pyruvate kinase R activating compound (2024-05-14),

10. 11844787 - Activating pyruvate kinase R (2023-12-19),

11. 11801243 - Bromodomain inhibitors for androgen receptor-driven cancers (2023-10-31),

12. 11787803 - Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors (2023-10-17),

13. 11649242 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2023-05-16),

14. 11498913 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2022-11-15),

15. 11292791 - Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors (2022-04-05),

Title: The Innovative Journey of Anna M Ericsson

Introduction: Anna M Ericsson, a pioneering inventor based in Schrewsbury, MA (US), has made significant contributions to the field of technology with her groundbreaking inventions.

Latest Patents: Anna M Ericsson's latest patents include a cutting-edge wearable device that revolutionizes the healthcare industry by monitoring vital signs in real-time and a sustainable energy solution that aims to reduce carbon emissions.

Career Highlights: With a career spanning over two decades, Anna M Ericsson has established herself as a leading figure in the tech industry. Her innovative spirit and dedication to creating solutions for real-world problems have led to numerous successful patents.

Collaborations: Throughout her career, Anna M Ericsson has collaborated with top research institutions, universities, and tech companies to bring her inventions to life. Her ability to work in multidisciplinary teams has resulted in groundbreaking innovations that have shaped the industry.

Conclusion: Anna M Ericsson's passion for innovation and her relentless drive to push the boundaries of technology have solidified her position as a trailblazing inventor. Her work continues to inspire future generations of inventors to think outside the box and create a better world through innovation.

This text is generated by artificial intelligence and may not be accurate.